XT
GALT icon

XTX Topco’s Galectin Therapeutics GALT Stock Holding History

XTX Topco’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66.9K Buy
+14,422
New +$37.4K ﹤0.01% 3638
2026
Q1 		– Sell
-51,936
Closed -$216K – 4005
2025
Q4 		$216K Buy
+51,936
New +$273K 0.01% 2342
2025
Q3 		– Sell
-42,805
Closed -$90.3K – 2803
2025
Q2 		$90.3K Buy
42,805
+29,699
+227% +$44.4K ﹤0.01% 1903
2025
Q1 		$16K Sell
13,106
-4,556
-26% -$6.39K ﹤0.01% 2185
2024
Q4 		$22.8K Buy
+17,662
New +$42.3K ﹤0.01% 2019
2021
Q3 		– Sell
-12,419
Closed -$40K – 801
2021
Q2 		$40K Buy
+12,419
New +$44.2K 0.01% 741

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

XTX Topco's GALT Position: Q2 2026 in Review

XTX Topco opened a new position in Galectin Therapeutics (GALT) in Q2 2026: 14,422 shares worth $66.9K. The stake represents ﹤0.01% of the portfolio and ranks #3638 among its holdings. This is a return to the name: XTX Topco previously reported a position in GALT as recently as Q4 2025.

XTX Topco first reported a position in GALT in Q2 2021 and has held it in 6 quarters since. The position peaked at $216K in Q4 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • XTX Topco held 14,422 shares of Galectin Therapeutics worth $66.9K as of Q2 2026.
  • Galectin Therapeutics was a new XTX Topco position in Q2 2026.
  • Galectin Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3638 holding.
  • XTX Topco first reported a position in Galectin Therapeutics in Q2 2021 and has held it in 6 quarters since.
  • XTX Topco's Galectin Therapeutics position peaked at $216K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.